Results 31 to 40 of about 20,261,647 (304)

Hepatitis C [PDF]

open access: yesThe Lancet, 2015
Hepatitis C virus (HCV) infection is a major health problem worldwide. The effects of chronic infection include cirrhosis, end-stage liver disease, and hepatocellular carcinoma. As a result of shared routes of transmission, co-infection with HIV is a substantial problem, and individuals infected with both viruses have poorer outcomes than do peers ...
Webster, D, Klenerman, P, Dusheiko, G
openaire   +2 more sources

HBV pregenome RNA as a predictor of spontanous HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients

open access: yesBMC Gastroenterology, 2023
Background Previous studies have indicated that HBV pregenome RNA (HBV pgRNA) could predict HBeAg seroconversion among the chronic hapatitis B (CHB) patients treated with pegylated interferon (Peg-IFN) or nucleos(t)ide analogues (NAs).
Guangjun Song   +6 more
doaj   +1 more source

Hepatitis C action plan for Scotland : phase II (May 2008 - March 2011) [PDF]

open access: yes, 2008
In 2004, the Scottish Government recognised that 'Hepatitis C is one of the most serious and significant public health risks of our generation' [1]. By December 2006, Health Protection Scotland (HPS) estimated that 50,000 people in Scotland had been ...
Brown, G.   +8 more
core   +2 more sources

Hepatitis C and hepatic steatosis [PDF]

open access: yesQJM, 2010
Hepatic steatosis is commonly seen in patients with chronic hepatitis C infection, and the two together have a greater association than by chance alone. Hepatitis C virus is closely associated with lipid metabolism throughout its lifecycle. Hepatic steatosis is more common in genotype 3 infection, due to direct viral effects including through ...
J H, Patel   +3 more
openaire   +2 more sources

A signature based on NKG2D ligands to predict the recurrence of hepatocellular carcinoma after radical resection

open access: yesCancer Medicine, 2023
Introduction Due to the high recurrence, the HCC prognosis remains poor. Yet, the biomarkers for predicting the recurrence of high‐risk patients are currently lacking.
Dongbo Chen   +8 more
doaj   +1 more source

SCREENING FOR HEPATITIS C Response from Hepatitis C Trust, BASL, BIA, BVHG, BSG, and BHIVA to article asking whether widespread screening for hepatitis C is justified [PDF]

open access: yes, 2015
This is the peer reviewed published version of the following article: Response from Hepatitis C Trust, BASL, BIA, BVHG, BSG, and BHIVA to article asking whether widespread screening for hepatitis C is justified, which has been published in final form at ...
Ustianowski, A   +6 more
core   +1 more source

Identification of the viral and cellular microRNA interactomes during SARS-CoV-2 infection

open access: yesCell Reports, 2023
Summary: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has had a tremendous impact worldwide. Mapping virus-host interactions is critical to understand disease progression.
Nicolas Fossat   +8 more
doaj   +1 more source

Analysis of Hepatitis C Virus Particle Heterogeneity in Immunodeficient Human Liver Chimeric fah-/- MiceSummary

open access: yesCellular and Molecular Gastroenterology and Hepatology, 2017
Background & Aims: Hepatitis C virus (HCV) is a leading cause of chronic liver diseases and the most common indication for liver transplantation in the United States.
Ursula Andreo   +10 more
doaj   +1 more source

Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development [PDF]

open access: yes, 2013
Background: Vitamin D insufficiency has been associated with the occurrence of various types of cancer, but causal relationships remain elusive. We therefore aimed to determine the relationship between genetic determinants of vitamin D serum levels and ...
Jörg Bojunga   +150 more
core   +3 more sources

SARS-CoV-2 Mpro inhibitor ensitrelvir: asymmetrical cross-resistance with nirmatrelvir and emerging resistance hotspots

open access: yesEmerging Microbes and Infections
SARS-CoV-2 main protease (Mpro) inhibitors are the first-line COVID-19 treatment. Nirmatrelvir is used worldwide, while ensitrelvir, licensed in Japan and Singapore, has received FDA fast-track designation.
Yuyong Zhou   +12 more
doaj   +1 more source

Home - About - Disclaimer - Privacy